Eyepoint Begins Pivotal Phase 3 Trial for Duravyu™ in DME
Phase 2 signals for EyePoint’s vorolanib intravitreal insert include an approximately 88% reduction in treatment burden at six months...
Surging Lung Cancer ADC Market: FDA Trials & Opportunity
Global lung cancer ADCs have moved from niche to scale: the new Kuick Research analysis pegs 2024 revenue at...
OX40 Targeted Therapy Trials & Market Opportunity Insight 2026
Across OX40/OX40L programs, concrete signals are emerging: in asthma, an amlitelimab-responsive subgroup reported more than a 70% reduction in...
Promising Pancreatic Cancer Data from Cellectar Biosciences
In three pancreatic ductal adenocarcinoma xenograft models (PANC-1, MIA PaCa-2, and BxPC-3), Cellectar’s actinium-225 phospholipid ether conjugate CLR 225...
First Pharma to Restore Sense of Smell? Inside the FLAVOR Trial Quest to Treat Postviral Olfactory Loss
In this interview, I’m talking with Rick Geoffrion, Founder, President, and CEO of Cyrano Therapeutics, about FLAVOR, a Phase...
“Minutes, Not Days”: Site-Centric AI and Clinical Trial Experience
The coordinator stared at a 400-page EHR export, convinced the week was lost—until an AI pre-screen flagged 23 likely-eligible...
How Small Biotechs Navigate Clinical Trial Vendor Oversight
At SCOPE Europe 2025, a panel on vendor identification, selection, and management highlighted a pragmatic blueprint for small biopharma:...
Shining Light on Women’s Health: A New Non-Drug Vaginal Therapy
In this interview, I spoke with Dr. Melanie Santos, Chief Medical Officer at Cern Corporation, about a novel low...
New Analysis Supports Genetic Tool for Depression Treatment
In a retrospective re-analysis of Sanofi’s prior Phase 2 Major Depressive Disorder study (NCT00358631), patients receiving the vasopressin V1b...
Cidara Presents Late-Breaking Phase 2 CD388 Clinical Data
Cidara will deliver late-breaking Phase 2 data for its long-acting influenza prophylactic CD388 at ID Week on October 20,...